Epigenetic modifiers in immunotherapy: A focus on checkpoint inhibitors

Immunotherapy

Volumn 8, Issue 6, 2016, Pages 705-719

  Terranova Barberio, Manuela ^a   Thomas, Scott ^a   Munster, Pamela N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; checkpoint inhibitors; DNMT inhibitor; epigenetics; HDAC inhibitor; immunotherapy

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; BMS 936559; BMS 986016; CC 90002; CD134 ANTIGEN; CD47 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; DURVALUMAB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HU5F9 G4; IPILIMUMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIRILUMAB; MEDI 6469; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN LAG 3; REGULATOR PROTEIN; TICILIMUMAB; TRX 518; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOLOGIC FACTOR; T LYMPHOCYTE RECEPTOR;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; DEACETYLATION; DNA METHYLATION; EPIGENETICS; HISTONE ACETYLATION; HUMAN; IMMUNE CHECKPOINT; IMMUNE RESPONSE; IMMUNITY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; REVIEW; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CD8+ T LYMPHOCYTE; GENETIC EPIGENESIS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; EPIGENESIS, GENETIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS;

EID: 84971294694     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0014     Document Type: Review

References (128)

1. Wolffe AP. Chromatin: structure and function. 1-477, Academic Press, San Diego, CA, USA (1999).
2. Ramachandran S, Ient J, Gottgens EL, Krieg AJ, Hammond EM. Epigenetic therapy for solid tumors: highlighting the impact of tumor hypoxia. Genes (Basel) 6(4), 935-956 (2015).
3. Kouzarides T. Chromatin modifcations and their function. Cell 128(4), 693-705 (2007).
4. Cohen I, Poreba E, Kamieniarz K, Schneider R. Histone modifers in cancer: friends or foes? Genes Cancer 2(6), 631-647 (2011).
5. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifcations. Cell Res. 21(3), 381-395 (2011).
6. Sarkar S, Goldgar S, Byler S, Rosenthal S, Heerboth S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics 5(1), 87-94 (2013).
7. Sarkar S, Horn G, Moulton K et al. Cancer development, progression, and therapy: an epigenetic overview. Int. J. Mol. Sci. 14 (10), 21087-21113 (2013).
8. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer 94(8), 1087-1092 (2006).
9. Housman G, Byler S, Heerboth S et al. Drug resistance in cancer: an overview. Cancers (Basel) 6 (3), 1769-1792 (2014).
10. Song SH, Han SW, Bang YJ. Epigenetic-based therapies in cancer: progress to date. Drugs 71(18), 2391-2403 (2011).
11. Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with 'epigenetic' drugs: an update. Mol. Oncol. 6(6), 657-682 (2012).
12. Budillon A, Bruzzese F, Di Gennaro E, Caraglia M. Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr. Drug Targets 6(3), 337-351 (2005).
13. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6(1), 38-51 (2006).
14. Arrighetti N, Corno C, Gatti L. Drug combinations with HDAC inhibitors in antitumor therapy. Crit. Rev. Oncog. 20(1-2), 83-117 (2015).
15. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 107(4), 600-608 (2009).
16. Thurn K T, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 7(2), 263-283 (2011).
17. Ocker M. Deacetylase inhibitors-focus on non-histone targets and effects. World J. Biol. Chem. 1(5), 55-61 (2010).
18. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25(1), 84-90 (2007).
19. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27(32), 5459-5468 (2009).
20. Budillon A, Di Gennaro E, Bruzzese F, Rocco M, Manzo G, Caraglia M. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. Recent Pat. Anticancer Drug Discov. 2(2), 119-134 (2007).
21. Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim. Biophys. Acta 1799 (10-12), 717-725 (2010).
22. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247-1252 (2007).
23. O'connor OA, Horwitz S, Masszi T et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal Phase II BELIEF (CLN-19) study. J. Clin. Oncol. 33(23), 2492-2499 (2015).
24. San-Miguel JF, Hungria VT, Yoon SS et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind Phase 3 trial. Lancet Oncol. 15(11), 1195-1206 (2014).
25. Thomas S, Thurn KT, Raha P, Chen S, Munster PN. Effcacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One 8(7), e68973 (2013).
26. Di Gennaro E, Piro G, Chianese MI et al. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Br. J. Cancer 103 (11), 1680-1691 (2010).
27. Terranova-Barberio M, Roca MS, Zotti AI et al. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget doi:10.18632/oncotarget.6802 (2015) (Epub ahead of print).
28. Leone A, Roca MS, Ciardiello C et al. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. Free Radic. Biol. Med. 89287-299 (2015).
29. Munster PN, Thurn KT, Thomas S et al. A Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 104 (12), 1828-1835 (2011).
30. Thomas S, Aggarwal R, Jahan T et al. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann. Oncol. doi:10.1093/annonc/mdw044 (2016) (Epub ahead of print).
31. Kim MS, Kwon HJ, Lee YM et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7(4), 437-443 (2001).
32. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 67(11), 5064-5066 (2007).
33. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006).
34. Chik F, Szyf M, Rabbani SA. Role of epigenetics in cancer initiation and progression. Adv. Exp. Med. Biol. 72091-104 (2011).
35. Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv. Exp. Med. Biol. 7543-29 (2013).
36. Kareta MS, Botello ZM, Ennis JJ, Chou C, Chedin F. Reconstitution and mechanism of the stimulation of de novo methylation by human DNMT3L. J. Biol. Chem. 281(36), 25893-25902 (2006).
37. Bestor TH. The DNA methyltransferases of mammals. Hum. Mol. Genet. 9(16), 2395-2402 (2000).
38. Xu GL, Bestor TH, Bourc'his D et al. Chromosome instability and immunodefciency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402 (6758), 187-191 (1999).
39. Gonzalo S, Jaco I, Fraga MF et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat. Cell Biol. 8(4), 416-424 (2006).
40. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99(3), 247-257 (1999).
41. Jacinto FV, Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 22(4), 247-253 (2007).
42. Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anti Cancer Res. 33(8), 2989-2996 (2013).
43. Yang H, Bueso-Ramos C, Dinardo C et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6), 1280-1288 (2014).
44. Orskov AD, Treppendahl MB, Skovbo A et al. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: a rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 6(11), 9612-9626 (2015).
45. Huls G. Azacitidine in AML: a treatment option? Blood 126(3), 283-284 (2015).
46. Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther. Clin. Risk Manag. 3(5), 807-817 (2007).
47. Curran MP. Decitabine: a review of its use in older patients with acute myeloid leukaemia. Drugs Aging 30(6), 447-458 (2013).
48. Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics 2(1), 71-86 (2010).
49. Juergens RA, Wrangle J, Vendetti FP et al. Combination epigenetic therapy has effcacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1(7), 598-607 (2011).
50. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot Phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8(4), 358-368 (1997).
51. Momparler RL, Ayoub J. Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34 (S uppl. 4), S111-115 (2001).
52. Nakamura K, Nakabayashi K, Htet Aung K et al. DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status. PLoS One 10(3), e0120545 (2015).
53. Napso T, Fares F. Zebularine induces prolonged apoptosis effects via the caspase-3/PARP pathway in head and neck cancer cells. Int. J. Oncol. 44 (6), 1971-1979 (2014).
54. Helin K, Dhanak D. Chromatin proteins and modifcations as drug targets. Nature 502(7472), 480-488 (2013).
55. Daigle SR, Olhava EJ, Therkelsen CA et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20(1), 53-65 (2011).
56. Liu F, Li F, Ma A et al. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. J. Med. Chem. 56 (5), 2110-2124 (2013).
57. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7(3), 299-313 (2010).
58. Wu C, Jin X, Yang J et al. Inhibition of EZH2 by chemo-and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer. Oncotarget 7(3), 3440-3452 (2016).
59. Song X, Gao T, Wang N et al. Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer. Sci. Rep. 620864 (2016).
60. Park J, Thomas S, Munster PN. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics 7(4), 641-652 (2015).
61. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258 (1996).
62. Jenkins MK, Schwartz RH. Antigen presentation by chemically modifed splenocytes induces antigen-specifc T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165 (2), 302-319 (1987).
63. Baxter AG, Hodgkin PD. Activation rules: the two-signal theories of immune activation. Nat. Rev. Immunol. 2(6), 439-446 (2002).
64. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical beneft in melanoma patients. Clin. Cancer Res. 19(19), 5300-5309 (2013).
65. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol. 157(1), 9-19 (2009).
66. Callahan MK, Wolchok JD. At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy. J. Leukoc. Biol. 94(1), 41-53 (2013).
67. Woo SR, Turnis ME, Goldberg MV et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72(4), 917-927 (2012).
68. Schaer DA, Cohen AD, Wolchok JD. Anti-GITR antibodies-potential clinical applications for tumor immunotherapy. Curr. Opin. Investig. Drugs 11(12), 1378-1386 (2010).
69. Romagne F, Vivier E. Natural killer cell-based therapies. F1000 Med. Rep. 39 (2011).
70. Hammers HJ, Plimack ER, Infante JR et al. Expanded cohort results from CheckMate 016: a Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 33 (15- Su p p l.), 4516 (2015).
71. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23-34 (2015).
72. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol. Rev. 229(1), 67-87 (2009).
73. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
74. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
75. Kamphorst AO, Ahmed R. Manipulating the PD-1 pathway to improve immunity. Curr. Opin. Immunol. 25(3), 381-388 (2013).
76. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24(2), 207-212 (2012).
77. Park JJ, Omiya R, Matsumura Y et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116 (8), 1291-1298 (2010).
78. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 120(7), 1412-1421 (2012).
79. Llosa NJ, Cruise M, Tam A et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5(1), 43-51 (2015).
80. Wimberly H, Brown JR, Schalper K et al. PD-L1 expression correlates with tumor-infltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol. Res. 3(4), 326-332 (2015).
81. Ali HR, Glont SE, Blows FM et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infltrating lymphocytes. Ann. Oncol. 26(7), 1488-1493 (2015).
82. Loi S, Michiels S, Salgado R et al. Tumor infltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab beneft in early breast cancer: results from the FinHER trial. Ann. Oncol. 25(8), 1544-1550 (2014).
83. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 18(24), 6580-6587 (2012).
84. Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S. Immunotherapy in tumors. Dtsch Arztebl. Int. 112 (48), 809-815 (2015).
85. FDA approves Opdivo to treat advanced form of kidney cancer. www.accessdata.fda.gov/drugsatfda-docs/label/2015/125554s012lbl.pdf
86. FDA approves Keytruda for advanced non-small cell lung cancer. www.fda.gov/newsevents/newsroom/pressannouncements/ucm465444.html
87. Linch SN, Mcnamara MJ, Redmond WL. OX40 agonists and combination immunotherapy: putting the pedal to the metal. Front. Oncol. 534 (2015).
88. Curti BD, Kovacsovics-Bankowski M, Morris N et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73(24), 7189-7198 (2013).
89. Sanmamed MF, Pastor F, Rodriguez A et al. Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin. Oncol. 42(4), 640-655 (2015).
90. Cohen AD, Schaer DA, Liu C et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 5 (5), e10436 (2010).
91. Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J. Transl. Med. 1236 (2014).
92. Mitsui J, Nishikawa H, Muraoka D et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin. Cancer Res. 16 (10), 2781-2791 (2010).
93. Pruitt SK, Boczkowski D, De Rosa N et al. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur. J. Immunol. 41(12), 3553-3563 (2011).
94. Wiersma Valerie R, van Bommel Peter E, De Bruyn Marco, Helfrich Wijnand, Bremer Edwin. CD47, a multi-facetted target for cancer immunotherapy. In: Atlas of Genetics and Cytogenetics in Oncology and Haematology. (2014).http://atlasgeneticsoncology.org/Deep/CD47TumAndImmunoID20140.html
95. Kohrt HE, Thielens A, Marabelle A et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123(5), 678-686 (2014).
96. Kohrt HE, Houot R, Goldstein MJ et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117(8), 2423-2432 (2011).
97. West AC, Smyth MJ, Johnstone RW. The anticancer effects of HDAC inhibitors require the immune system. Oncoimmunology 3 (1), e27414 (2014).
98. Chumsri S, Lee M-J, Tomita Y et al. Epigenetic immune modulation by entinostat in breast cancer: correlative analysis of ENCORE 301 trial. Cancer Res. 76(4 Suppl.), Abstract P2-11-10 (2016).
99. Shen L, Ciesielski M, Ramakrishnan S et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One 7(1), e30815 (2012).
100. Chumsri S, Necela B, Ordentlich P et al. Immunomodulatory effects of entinostat on PD-L1 and MHC class I and II in different subtypes of breast cancer. Cancer Res. 76(4 Suppl.), Abstract P2-04-02 (2016).
101. Oki Y, Buglio D, Zhang J et al. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer J. 4 e236 (2014).
102. Kim K, Skora AD, Li Z et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111(32), 11774-11779 (2014).
103. Lampen MH, Van Hall T. Strategies to counteract MHC-I defects in tumors. Curr. Opin. Immunol. 23(2), 293-298 (2011).
104. Powers JJ, Maharaj KK, Sahakian E et al. Histone deacetylase 6 (HDAC6) as a regulator of immune checkpoint molecules in chronic lymphocytic leukemia (CLL). Blood 124(21), 3311 (2014).
105. Woods DM, Sodre AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol. Res. doi:10.1158/2326-6066. CIR-15-0077-T (2015) (Epub ahead of print).
106. Wong DJ, Rao A, Avramis E et al. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol. Res. 2(5), 459-468 (2014).
107. Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget 5(16), 6558-6572 (2014).
108. Pan F, Fan H, Liu Z, Jiang S. T cell signaling targets for enhancing regulatory or effector function. Sci. Signal 5 (235), doi:10.1126/scisignal. 2003364 (2012) (Epub ahead of print).
109. Akimova T, Beier UH, Liu Y, Wang L, Hancock WW. Histone/protein deacetylases and T-cell immune responses. Blood 119(11), 2443-2451 (2012).
110. Akimova T, Ge G, Golovina T et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin. Immunol. 136(3), 348-363 (2010).
111. Beier UH, Wang L, Han R, Akimova T, Liu Y, Hancock WW. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specifc mechanisms. Sci. Signal 5(229), doi: 10.1126/scisignal.2002873 (2012) (Epub ahead of print).
112. Xiao H, Jiao J, Wang L et al. HDAC5 controls the functions of Foxp3 T-regulatory and CD8 T cells. Int. J. Cancer doi:10.1002/ijc.29979 (2015) (Epub ahead of print).
113. Bridle BW, Chen L, Lemay CG et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol. Ther. 21(4), 887-894 (2013).
114. Christiansen AJ, West A, Banks KM et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc. Natl Acad. Sci. USA 108(10), 4141-4146 (2011).
115. Saleh MH, Wang L, Goldberg MS. Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol. Immunother.doi: 10.1007/s00262-015-1776-3 (2015) (Epub ahead of print).
116. Simova J, Pollakova V, Indrova M et al. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. Br. J. Cancer 105(10), 1533-1541 (2011).
117. Serrano A, Castro-Vega I, Redondo M. Role of gene methylation in antitumor immune response: implication for tumor progression. Cancers (Basel) 3(2), 1672-1690 (2011).
118. Li H, Chiappinelli KB, Guzzetta AA et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5(3), 587-598 (2014).
119. Heninger E, Krueger TE, Lang JM. Augmenting antitumor immune responses with epigenetic modifying agents. Front. Immunol. 629 (2015).
120. Costantini B, Kordasti SY, Kulasekararaj AG et al. The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica 98(8), 1196-1205 (2013).
121. Wang L, Amoozgar Z, Huang J et al. Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model. Cancer Immunol. Res. 3(9), 1030-1041 (2015).
122. Youngblood B, Oestreich KJ, Ha SJ et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specifc CD8(+) T cells. Immunity 35 (3), 400-412 (2011).
123. Wrangle J, Wang W, Koch A et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4(11), 2067-2079 (2013).
124. Roulois D, Loo Yau H, Singhania R et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162(5), 961-973 (2015).
125. Chiappinelli KB, Strissel PL, Desrichard A et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162(5), 974-986 (2015).
126. Peng D, Kryczek I, Nagarsheth N et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527(7577), 249-253 (2015).
127. Nagarsheth N, Peng D, Kryczek I et al. PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell traffcking in colon cancer. Cancer Res. 76(2), 275-282 (2016).
128. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14(4), 847-856 (2015).